Citigroup Inc. lowered shares of Celgene Corporation (NASDAQ:CELG) from a buy rating to a neutral rating in a research report report published on Friday morning, Marketbeat reports.

CELG has been the topic of a number of other reports. Oppenheimer Holdings, Inc. restated an outperform rating and set a $175.00 target price (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the company a buy rating in a research report on Thursday, July 27th. BMO Capital Markets restated an outperform rating and set a $160.00 target price (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the company a buy rating in a research report on Wednesday, July 26th. Finally, Vetr downgraded shares of Celgene Corporation from a buy rating to a hold rating and set a $145.17 price target on the stock. in a research report on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $149.71.

Shares of Celgene Corporation (NASDAQ:CELG) opened at 121.33 on Friday. The company has a 50 day moving average of $140.79 and a 200-day moving average of $130.41. The company has a market capitalization of $94.92 billion, a P/E ratio of 37.58 and a beta of 1.88. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $147.17.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the prior year, the company posted $1.44 EPS. The company’s revenue was up 18.7% compared to the same quarter last year. On average, equities analysts anticipate that Celgene Corporation will post $7.33 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Downgraded by Citigroup Inc.” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/10/23/celgene-corporation-celg-downgraded-by-citigroup-inc.html.

In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 46,233 shares of company stock valued at $6,268,259 in the last ninety days. Insiders own 0.95% of the company’s stock.

A number of institutional investors have recently made changes to their positions in CELG. Neuberger Berman Group LLC lifted its holdings in shares of Celgene Corporation by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after buying an additional 71,729 shares in the last quarter. Lincoln Capital Corp lifted its holdings in shares of Celgene Corporation by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after buying an additional 185 shares in the last quarter. Grisanti Capital Management LLC acquired a new stake in shares of Celgene Corporation during the second quarter worth $3,616,000. Swiss National Bank lifted its holdings in shares of Celgene Corporation by 27.2% during the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Celgene Corporation by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after buying an additional 54,210 shares in the last quarter. 79.24% of the stock is owned by institutional investors and hedge funds.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.